Endogenous Lithium Clearance in Acute Kidney Injury
1 other identifier
observational
20
1 country
1
Brief Summary
Critically ill patients are at high risk of developing acute kidney injury (AKI). Lithium is freely filtrated at the glomerulus and almost completely reabsorbed in the proximal tubule, which provides a quantitative estimation of proximal tubule reabsorption. The investigators hypothesized that endogenous lithium reabsorption is impaired in the early stages of critical illness. Investigators would like to study 10 ICU patients with AKI diagnosed, 10 patients without AKI, and 10 healthy controls.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Aug 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 31, 2023
CompletedStudy Start
First participant enrolled
August 1, 2023
CompletedFirst Posted
Study publicly available on registry
August 8, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 20, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 20, 2025
CompletedJune 22, 2025
May 1, 2025
1.8 years
July 31, 2023
June 17, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Renal lithium clearance
Clearance of lithium from the body
2 days
Study Arms (2)
Group 1
ICU patients with AKI
Group 2
ICU patients with normal renal function
Interventions
Eligibility Criteria
Critically ill patients and healthy controls
You may qualify if:
- ICU patients diagnosed with AKI, without AKI and healthy controls
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Hospital of North Norway
Tromsø, Troms, 9038, Norway
Biospecimen
Urine and blood
Study Officials
- PRINCIPAL INVESTIGATOR
Lars MG Ytrebø, MD PhD
University Hospital of North Norway
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 31, 2023
First Posted
August 8, 2023
Study Start
August 1, 2023
Primary Completion
May 20, 2025
Study Completion
May 20, 2025
Last Updated
June 22, 2025
Record last verified: 2025-05
Data Sharing
- IPD Sharing
- Will not share